EIF4G1 and neoplasm: These aspects can explain the results obtained for patient P03, who had only the EIF4G1 mutation detected in urine components (one out of eight somatic mutations identified in her tumor tissue DNA); or for patient P04, who had all three somatic mutations (SERBP1, WTAP, and PHF5A) in very high VAFs in tumor tissue (97.26%, 98.63%, and 97.22%, respectively—Table 2) and only two of them (WTAP and PHF5A) detected in DNA of body fluids before and during patient monitoring (Table S4; Figure 2).